Method for producing prostaglandin
Patent Information
- Application Number
- CA3132572
- Authority / Receiving Office
- CA · CA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-02-21
- Filing Date
- 2020-02-21
- Publication Date
- 2026-10-13
- Estimated Expiration
- 2040-02-21
AI Technical Summary
Current methods for producing prostaglandin derivatives require purification through column chromatography, increase the number of synthesis steps, and use stoichiometric amounts of optically active reagents, leading to economic and environmental burdens.
A method involving catalytic hydrogen reduction using an optically active catalyst to introduce hydroxy groups on the side chain with high stereoselectivity, employing a metal complex, inorganic base, and specific solvents to efficiently produce prostaglandin derivatives.
This method allows for the high stereoselective introduction of hydroxy groups on the side chain, reducing the number of steps and reagent usage, thereby enhancing the economic and environmental sustainability of prostaglandin production.
Abstract
Description
<DP=1>²CA 03132572 2021-09-03²FP20-0019-00²DESCRIPTION²Title of Invention²METHOD FOR PRODUCING PKROSTAGLANDIN² Technical Field²
[0001] The present invention relates to a method for producing²pro staglandins .²Background Art²
[0002] Prostaglandin (PG) is a general term for a group of endogenous² physiologically active substances synthesized by the metabolism of²arachidonic acid in vivo with cyclooxygenase. There are many types ²of prostaglandins, and, for example, prostaglandin H2, prostaglandin ²D2, prostaglandin El, prostaglandin E2, prostaglandin F2a, and ²prostaglandin 12 are known. Prostaglandins are involved in a variety² of physiological functions via their specific G protein-coupled²receptors.²
[0003] The chemical structure of prostaglandins includes a ²cyclopentane ring having 4 asymmetric carbon atoms and 2 aliphatic ²side chains. Therefore, it has been focused upon as a target for²synthesis studies or an idea for drug development for a long time, and²various prostaglandin derivatives have been developed so far. ²(3 aS ,4R,5S ,6aR)-(+)-hexahydro-5-hydroxy-4-(hydroxymethyl)-2H-cycl ²openta[b]furan-2-one used as its common intermediate is also called ²"Corey lactone." The chemical structures of Corey lactone and typical²commercially available prostaglandin derivatives are shown below.²1²Date Recue / Date Received 2021-09-03²<DP=2>²CA 03132572 2021-09-03²FP20-0019-00².r0H 1,(DH 0²0²0 HO²0 OH²_²HO OH HO OH HO OH²dinoprostone dinoprost limaprost²0²0 0²HO² 0²Ph Ph²Ho OH H H6 OH HO OH OH²alprostadil bimatoprost latanoprost Corey ²lactone²
[0004] After development of Corey lactones, the main challenge in the ²synthesis of prostaglandin derivatives is control of the stereochemistry ²of the substituents present in side chains. In particular, more studies² have been conducted in order to introduce hydroxy groups having a²desired stereochemistry. In Patent Literature 1, a method in which ²corresponding carbonyl groups are reduced and diastereomers are then ²separated through column chromatography and a method in which ²substituents are additionally introduced at hydroxy groups generated by²the reduction, and the optical purity is increased by crystallization or the²like have been reported. Patent Literature 2 discloses a method in ²which side chain units having a desired stereochemistry are bonded to ²cyclopentane derivatives according to a coupling reaction. In Patent ²Literature 3, reduction of corresponding carbonyl groups using an² optically active reducing agent such as (-)-DIP-chlorideTM has been²studied.²Citation List²Patent Literature²
[0005] [Patent Literature 1] WO 2012 / 011128 Al² [Patent Literature 2] US 2007 / 167641 Al²2²Date Recue / Date Received 2021-09-03²<DP=3>²CA 03132572 2021-09-03²FP20-0019-00²[Patent Literature 3] CN 105985371 Al²[Patent Literature 4] EP 2837621 Al²[Patent Literature 5] WO 2002 / 096898 A2²[Patent Literature 6] WO 2007 / 091697 A2² [Patent Literature 7] US 6248783 B1²[Patent Literature 8] US 3726983 B1²[Patent Literature 9] US 2009 / 259066 Al²Non Patent Literature²
[0006] [Non-Patent Literature 1] E. J. Corey et al., J. Am. Chem.² Soc., 1969, 91, 5675.²Summary of Invention²Technical Problem²
[0007] However, in the above methods, it is necessary to perform²purification through column chromatography, increase the number of² steps according to derivatization, and use a stoichiometric amount of an²optically active reagent, and there are concerns about the economic ²burden and environmental burden. Therefore, an object of the present ²invention is to provide a method for efficiently producing ²prostaglandins using an optically active catalyst and a synthetic²intermediate thereof.²Solution to Problem²
[0008] The present invention provides the following [1] to [6].²[1] A method for producing a compound represented by Formula (la),²(lb), or (lc):²3²Date Recue / Date Received 2021-09-03²<DP=4>²CA 03132572 2021-09-03²FP20-0019-00²HQ f_22 0 IR.2 F10.. R2²1 0_,,, / 1²OH² OH OH 01 H²(1 a) (1 b) (1c)²in the formula, R1 is a C1_8 alkyl group that is optionally ²substituted with a phenyl group, R2 is a group represented by Formula ²(2a), (2b), or (2c):²¨\__ / -----µ40²_²R3 R3 R3² (2a) (2b) (2c)²in the formula, R3 is a hydroxy group, a C1-3 alkoxy group, a ²mono(C1_3 alkyl)amino group or a di(C1_3 alkyl)amino group;²the method comprising a step of reducing a compound ²represented by Formula (3) in the presence of a metal complex²represented by Formula (5), an inorganic base, and a solvent under a²hydrogen atmosphere to obtain a compound represented by Formula (4):²0 0²A²c . \ Ar2 Ar2²i H2²Q :. Q :-²0......R1²W Ru Z²_ _²1 00 ²----² / ² Ar2\ Ar2 H2²Arl Arl²(3) (4) (5)²in the formula, Arl is an aryl group that is optionally substituted, ²each Ai' is independently a phenyl group, a 3,5-dimethylphenyl² group, or a 3,5-di(tert-butyl)-4-methoxyphenyl group,²4²Date Recue / Date Received 2021-09-03²<DP=5>²CA 03132572 2021-09-03²FP20-0019-00²W is a biphenyl group that is optionally substituted or a ²binaphthyl group that is optionally substituted,²Z is an ethylene group that is substituted with two or more ²groups selected from among a phenyl group, a C1_3 alkoxyphenyl group² and a C1-8 alkyl group, and L is a chlorine atom or if Z has a phenyl²group or a C1-3 alkoxyphenyl group, L is one of carbon atoms ²constituting the phenyl group or the C1-3 alkoxyphenyl group.²[2] The method according to [1], wherein the solvent comprises at least ²one solvent selected from among ethers, alcohols, acetonitrile and water.²[3] The method according to [1] or [2], wherein Arl is a phenyl group,²and Ai' is a 3,5-dimethylphenyl group.²[4] The method according to any of [1] to [3], wherein R1 is a n-pentyl ²group, a 2-methylhexyl group, or a 2-phenylethyl group.²[5] The method according to any of [1] to [4], further comprising a step²of reacting a compound represented by Formula (4) with a compound²represented by Formula (6) to obtain a compound represented by²Formula (7):²0²A.²Q z-²0.....R1²(:),,,a (:). ²0. / ²x²1 Ar3²Ar3 Ar', ²(6) (7)²in the formula, R1 is a C1_8 alkyl group that is optionally² substituted with a phenyl group, Arl and Ai' are each independently an²aryl group, and X is a leaving group.²5²Date Recue / Date Received 2021-09-03²<DP=6>²CA 03132572 2021-09-03²FP20-0019-00²[6] A compound represented by Formula (7'):²0²0......R²0-² / k A²%²--õ,²(7')²in the formula, R is a C1_8 alkyl group that is optionally ²substituted with a phenyl group, and A is a nitro group.² Advantageous Effects of Invention²
[0009] According to the present invention, when catalytic hydrogen ²reduction using an optically active catalyst is performed, it is possible to ²introduce hydroxy groups on the side chain with high stereoselectivity ²and it is possible to efficiently produce prostaglandin derivatives.² Description of Embodiments²
[0010] An embodiment of the present invention will be described in ²detail. In this specification, for convenience, a "compound represented ²by Formula (1)" and the like are referred to as a "compound (1)" and the ²like.²
[0011] An embodiment of the present invention is a method for²producing a compound (1a), (lb), or (1c).²6²Date Recue / Date Received 2021-09-03²<DP=7>²CA 03132572 2021-09-03²FP20-0019-00²HQ R2 0 R2 HQ R2²0......"õ_(..²OH - OH²OH²OH OH OH²(la) (1b) (1c)²
[0012] In Formula (la), (lb), or (1c), R1 is a C1-8 alkyl group that is ²unsubstituted or substituted with a phenyl group. The C1-8 alkyl group ²is a linear or branched alkyl group having 1 to 8 carbon atoms and may² be an optically active branched alkyl group. Examples of C1-8 alkyl²groups include a methyl group, an ethyl group, a 1-propyl group, a ²2-propyl group (also referred to as an isopropyl group), a 1-butyl group, ²a 2-methyl-l-propyl group (also referred to as an isobutyl group), a ²1-methyl-2-propyl group, a tert-butyl group, a 1-pentyl group, a²2-methyl-1-butyl group, a 3-pentyl group, a 3-methyl-1 -butyl group²(also referred to as an isopentyl group), a 2,2-dimethyl-l-propyl group ²(also referred to as a neopentyl group), a 1-hexyl group, a ²1-methyl-2-pentyl group, a 2-methyl-2-pentyl group, a ²3-methyl-2-pentyl group, a 1-heptyl group, a 2-heptyl group, a²2-methyl-l-hexyl group, a 2-ethyl-l-pentyl group, a 3-methyl-l-hexyl²group, a 3-ethyl-l-pentyl group, 3-heptyl group, a 4-heptyl group, a ²1-octyl group, a 2-octyl group, a 2-methyl-l-heptyl group, a ²3-ethyl-l-pentyl group, and a 3-propy1-1-butyl group. In addition, the ²C1-8 alkyl group substituted with a phenyl group is a group in which² some of hydrogen atoms constituting the above linear or branched alkyl²group having 1 to 8 carbon atoms are replaced with a phenyl group. ²Specific examples of the C1_8 alkyl group substituted with a phenyl²7²Date Recue / Date Received 2021-09-03²<DP=8>²CA 03132572 2021-09-03²FP20-0019-00²group include a phenylmethyl group (also referred to as a benzyl group), ²a 1-phenylethyl group, a 2-phenylethyl group, a 1-phenylpropyl group, ²and a 1-methyl-1-phenyl ethyl group.²
[0013] In Formula (la), (lb), or (1c), IV is a group represented by² Formula (2a), (2b), or (2c), and R3 is a hydroxy group, a C1-3 alkoxy²group, a mono(C1_3 alkyl)amino group, or a di(C1_3 alkyl)amino group.²_²R3 R3 R3²(2a) (2b) (2c)²
[0014] The C1_3 alkoxy group is a group composed of an oxygen atom ²to which a linear or branched alkyl group having 1 to 3 carbon atoms is² bonded. Examples of C1_3 alkoxy groups include a methoxy group, an²ethoxy group, a 1-propyloxy group, and a 2-propyloxy group (also ²referred to as an isopropyloxy group).²
[0015] The mono(C1_3 alkyl)amino group is a group composed of amino ²groups to which one linear or branched alkyl group having 1 to 3 carbon²atoms is bonded. Examples of mono(C1_3 alkyl)amino groups include²a monomethylamino group, a monoethylamino group, a ²mono(1-propyl)amino group, and a mono(2-propyl)amino group.²
[0016] The di(C1_3 alkyl)amino group is a group composed of amino ²groups to which two linear or branched alkyl groups having 1 to 3²carbon atoms are bonded. Examples of di(C1_3 alkyl)amino groups²include a N,N-dimethylamino group, a N-ethyl-N-methylamino group, a ²N,N-diethylamino group, a N-ethyl-N-(1-propyl)amino group, a ²N,N-di(1-propyl)amino group, and a N,N-di(2-propyl)amino group. ²
[0017] (Step 1)²8²Date Recue / Date Received 2021-09-03²<DP=9>²CA 03132572 2021-09-03²FP20-0019-00²The method according to the present embodiment comprises a ²step of reducing a compound (3) under a hydrogen atmosphere in the ²presence of a metal complex (5), an inorganic base, and a solvent to ²obtain a compound (4). In Formula (3) or (4), R1 has the same² definition as in Formula (1), and Arl is an aryl group that is optionally²substituted.²Ar2 Ar2²H2²r TI / N²Ru²0 )1 / I ) 0 N. L N----²\ 0²Q Ar2 Ar2 H2²:²(5)²0 oo²Step 1 z²0- H²1²1 Arl²Arl²(3) (4)²
[0018] The aryl group is an aromatic hydrocarbon group, and may be,²for example, an aromatic hydrocarbon group having 6 to 10 carbon² atoms. Examples of aryl groups include a phenyl group and a naphthyl²group. The aryl group is optionally substituted with a halogen atom ²(for example, a fluorine atom, a chlorine atom, a bromine atom, and an ²iodine atom), a C1_3 alkyl group, a C1_3 alkoxy group, or a cyano group. ²
[0019] In Formula (5), each Ar2 is independently a phenyl group, a²3,5-dimethylphenyl group, or a 3,5-di(tert-butyl)-4-methoxyphenyl²group. A group in which four Ar2's are the same group is preferable.²
[0020] In Formula (5), W is a biphenyl group that is optionally ²substituted or a binaphthyl group that is optionally substituted. In ²addition, (Ar2)2P-W-P(Ar2)2 is a bidentate ligand that can be coordinated ²9²Date Recue / Date Received 2021-09-03²<DP=10>²CA 03132572 2021-09-03²FP20-0019-00²to a ruthenium atom, and W is preferably a ²bis(methylenedioxyphenyl)group or a binaphthyl group which is a²single atropisomer. ²Examples of (Ar2)2P-W-P(Ar2)2 include²2,2 ' -bis(diphenylphosphino)-1,1' -binaphthyl ²(BINAP),² 2,2' -bis[di(p-tolyl)phosphino]-1,1' -binaphthyl (to1BINAP),²2,2' -bis [di(m-tolyl)pho sphino] -1,1' -binaphthyl,²2,2' -bis [di(3 ,5-xylyl)phosphino] -1, 1 ' -binaphthyl ²(xylBINAP),²2,2' -bis [di(p-t-butylphenyl)phosphino] -1, 1 ' -binaphthyl,²2,2' -bis[di(p-methoxyphenyl)phosphino]-1,1' -binaphthyl,²2,2' -bis [di(3 ,5-di-t-butyl-4-methoxyphenyl)phosphino] -1, 1 ' -binaphthyl,²2,2' -bis[di(cyclopentyl)phosphino]-1,1' -binaphthyl,²2,2 '-bis [di(cyclohexyl)pho sphino] -1, 1 ' -binaphthy1,2,2' -bis(diphenylpho²sphino)-5,5 ',6,6',7,7' ,8,8' -octahydro-1,1' -binaphthyl,²2,2 ' -bis(di-p-tolylphosphino)-5,5',6,6',7,7',8,8' -octahydro-1,1' -binapht²hyl,²2,2 ' -bis(di-m-tolylphosphino)-5,5 ',6,6',7,7' ,8,8' -octahydro-1,1' -binapht²hyl,²2,2 ' -bis(di-3,5-xylylphosphino)-5,5 ',6,6',7,7',8,8' -octahydro-1, 1 ' -²binap²hthyl (xyl-²H8-BINAP),²2,2 ' -bis(di-p-t-butylphenylphosphino)-5,5' ,6,6',7,7',8,8' -octahydro-1, 1 '²-binaphthyl,²2,2 ' -bis(di-p-methoxyphenylphosphino)-5,5 ',6,6',7,7',8,8' -octahydro-1,²1' -binaphthyl,²2,2 ' -bis(di-p-chlorophenylphosphino)-5,5',6,6',7,7',8,8' -octahydro-1,1'²-binaphthyl,²2,2 ' -bis(dicyclopentylphosphino)-5,5',6,6' ,7, 7' ,8,8' -octahydro-1,1' -bin² Date Recue / Date Received 2021-09-03²<DP=11>²CA 03132572 2021-09-03²FP20-0019-00²aphthyl,²2,2' -bis(dicyclohexylphosphino)-5,5',6,6 ',7, 7' ,8,8 ' -octahydro-1,1 ' -²bina²phthyl, ((4,4' ²-bi-1,3-benzodioxol)-5,5' -diyObis(diphenylphosphine)²(segphos),² (4,4' -bi-1,3-benzodioxol)-5,5' -diy1)bis(di(3,5-xylyl)phosphine)²(dm-segphos),²((4,4' -bi-1,3-benzodioxol)-5,5' -diy1)bis(di(3,5 -di-t-butyl-4-methoxyphe²nyl)phosphine),²((4,4' -bi-1,3-benzodioxol)-5,5' -diyObis(di(4-methoxyphenyl)phosphine²), ((4,4' -bi-1,3-²benzodioxol)-5,5' -diyObis(dicyclohexylphosphine),²((4,4' -bi-1,3-benzodioxol)-5,5' -diy1)bis(bis(3 ,5-di-t-butylphenyl)phosph²me), 2,2' -²bis(di-3,5-xylylphosphino)-6,6 ' -dimethoxy-1,1' -biphenyl²(xylyl-Me0-biphep),²2,2 ' -bis(diphenylphosphino)-6,6 ' -dimethy1-1,1-biphenyl,²2,2 ' -bis(di-p-tolylphosphino)-6,6' -dimethyl-1,1 '-biphenyl,²2,2 ' -bis(di-o-tolylphosphino)-6,6' -dimethyl-1,1 ' -biphenyl,²2,2 ' -bis(di-m-fluorophenylpho sphino)-6, 6' -dimethyl-1,1' -biphenyl,²2,2 ' -bis(diphenylphosphino)-6,6 ' -dimethoxy-1,1 ' -biphenyl,²2,2 ' -bis(di-p-tolylphosphino)-6,6' - dimethoxy-1, 1 ' -biphenyl,²2,2 ',6,6' -tetramethoxy-4,4' -bis(di-3,5-xyly1 phosphino)-3,3 ' -bipyridine²(xylyl-p-phos),²2,2 ',6,6' -tetramethoxy-4,4' -bis(diphenylphosphino)-3,3 ' -bipyridine,²2,2 ',6,6' -tetramethoxy-4,4' -bis(di-p-tolylphosphino)-3,3 ' -bipyridine,²2,2 ',6,6' -tetramethoxy-4,4' -bis(di-o-tolylphosphino)-3,3 ' -bipyridine,²4,12-bis(di-3,5-xylylphosphino)-[2.2]-paracyclophane,²4,12-bis(diphenylphosphino)-[2.2]-paracyclophane, 4,12-²11²Date Recue / Date Received 2021-09-03²<DP=12>²CA 03132572 2021-09-03²FP20-0019-00²bis (di-p-tolylpho sphino)- [2. 2]-paracyc lophane,²4,12-bis(di-o -tolylpho sphino)- [2. 2]-paracyc lophane,²1,1' -bis(2,4-diethylphosphotano)ferrocene,²1,13 -bis(diphenylpho sphino)-7,8-dihydro-6H-dib enzo [f,h]² [1,5] dioxonin,²1,13-bis(bis (3 ,5 -dimethylphenyl)pho sphino)-7,8-dihydro-6H-dib enzo [f,²h] [1,5] dioxonin (xylyl-C3-tunephos), and²6,6' -bis(bis(3,5-dimethylphenyl)phosphino)-2,2 ' ,3,3' -tetrahydro -5,5 '-bi ²-1,4-benzodioxine (xylyl-synphos).²
[0021] In Formula (5), Z may be an ethylene group substituted with two²or more groups selected from among a phenyl group, a C1-3 ²alkoxyphenyl group and a C1_8 alkyl group, and in this case, L is a²chlorine atom. H2N-Z-²NH2 is a bidentate ligand that can be²coordinated to a ruthenium atom. Examples of H2N-Z-NH2 include²(S,R)-1,2-diphenylethylenediamine,²(R,S)-1,2-diphenylethylenediamine,²1,2-bis(4-methoxyphenyl)ethylenediamine,²1-methyl-2,2-diphenylethylenediamine,²1-isobuty1-2,2-diphenylethylenediamine,²1-isopropyl-2,2-diphenylethylenediamine (DPIPEN),²1-methyl-2,2-bis(4-methoxyphenyl)ethylenediamine ²(DAMEN),²1-isobuty1-2,2-bis(4-methoxyphenypethylenediamine,²1-isopropyl-2,2-bis(4-methoxyphenyl)ethylenediamine ²(DAIPEN),²1-phenyl-2,2-bis(4-methoxyphenyl)ethylenediamine,²1,1-bis(4-methoxyphenyl)ethylenediamine (DAEN), and²1-isopropyl-2,2-bis(3-methoxyphenyl)ethylenediamine (3-²DAIPEN).²12²Date Recue / Date Received 2021-09-03²<DP=13>²CA 03132572 2021-09-03²FP20-0019-00²A preferable H2N-Z-NH2 is optically active²1,2-diphenylethylenediamine or²1-isopropyl-2,2-di(4-methoxyphenypethylenediamine.²
[0022] In addition, when Z has a phenyl group or a C1_3 alkoxyphenyl² group, one of carbon atoms constituting the phenyl group or C1-3²alkoxyphenyl group may be directly bonded to a ruthenium atom so that ²a ruthenabicyclo[2.2.1]heptane structure is formed.²
[0023] In the step 1, the compound (3) is dissolved in a solvent in a ²predetermined container, an inorganic base is added thereto and a gas²phase in the container is replaced with an inert gas. Next, after the²metal complex (5) is added thereto, a gas phase is replaced with a ²hydrogen gas, and the mixture is stirred under a hydrogen atmosphere ²for a predetermined time. The mixture is preferably vigorously stirred ²so that hydrogen gas in the gas phase is easily mixed into the reaction²solution.²
[0024] The solvent may be any solvent in which the compound (3) can ²be dissolved and which does not inhibit catalytic hydrogen reduction. ²Examples of solvents include aromatic hydrocarbons such as benzene, ²toluene, and xylene, aliphatic hydrocarbons such as hexane and heptane,² halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane,²chlorobenzene, and dichlorobenzene, ethers such as diethyl ether, ²diisopropyl ether, tetrahydrofuran, methyl tert-butyl ether, cyclopentyl ²methyl ether, and 2-methyl-tetrahydrofuran, alcohols such as methanol, ²ethanol, isopropyl alcohol, n-butyl alcohol, 2-butyl alcohol, tert-butyl²alcohol, ethylene glycol, propylene glycol, 1,2-propanediol, and²glycerin, acetonitrile, N,N-dimethylformamide (DMF) ,and²13²Date Recue / Date Received 2021-09-03²<DP=14>²CA 03132572 2021-09-03²FP20-0019-00²N,N-dimethylacetamide. These solvents may be used alone or may be ²used by being selectively mixed. Water may be incorporated as long ²as the compound (3) can still dissolve. A preferable solvent is at least ²one selected from among ethers, alcohols, acetonitrile and water.²
[0025] The amount of the solvent used is preferably an amount at which²the molar concentration of the compound (3) is 0.05 to 1.5 mol / L and ²more preferably an amount at which the molar concentration of the ²compound (3) is 0.1 to 0.9 mol / L.²
[0026] The inorganic base may be a basic inorganic salt. Examples of²inorganic bases include potassium carbonate, sodium carbonate, cesium²carbonate, potassium bicarbonate, sodium bicarbonate, potassium ²hydroxide, sodium hydroxide, tripotassium phosphate, trisodium ²phosphate, dipotassium hydrogen phosphate, disodium hydrogen ²phosphate, potassium dihydrogen phosphate, and sodium dihydrogen²phosphate.²
[0027] The amount of the inorganic base used may be 0.1 to 50²equivalents and is more preferably 1 to 20 equivalents with respect to²the number of moles of the metal complex (5).²
[0028] The amount of the metal complex (5) used varies depending on²the amount of the compound (3), reaction conditions and the type of the²metal complex (5), and is generally 0.1 to 25 mol%, and more ²preferably 1 to 5 mol% with respect to the number of moles of the ²compound (3).²
[0029] The reaction temperature varies depending on the type of the²solvent used, and the reaction can be performed at -50 to 50 C. A²preferable reaction temperature is -20 to 10 C. If the reaction²14²Date Recue / Date Received 2021-09-03²<DP=15>²CA 03132572 2021-09-03²FP20-0019-00²temperature is too low, the solubility of the compound (3) may decrease, ²and if the reaction temperature is too high, the compound (3), the ²compound (4) or the metal complex (5) may be decomposed.²
[0030] The reaction may be performed at a normal pressure or may be² performed under a predetermined pressure. For example, the reaction²may be performed by a method in which hydrogen gas is sealed into a ²rubber balloon and the balloon is connected to the opening of the ²container (a flask, etc.). Since hydrogen gas is consumed as the ²reaction proceeds, a sufficient amount of hydrogen gas is used, or²hydrogen gas is supplemented during the reaction.²
[0031] When the reaction is completed, a gas phase in the container is ²replaced with an inert gas, and as necessary, the metal complex is then ²removed by filtration, and can be purified by generally used purification ²methods such as extraction, crystallization, distillation, and various²types of chromatography alone or an appropriate combination thereof.²
[0032] (Step 2)²The method according to the present embodiment may further ²comprise a step of reacting the compound (4) with a compound (6) to ²obtain a compound (7). In Formula (7), R1 and Arl have the same² definitions as in Formula (4).²0 x 0²1 ,²0"1(`²0......",.R1 (6)²__________________________________ v.-²bH Step 2 6²0 b 0-b c). / ² Y I , Ar3² Arl Ar'²(4) (7)² Date Recue / Date Received 2021-09-03²<DP=16>²CA 03132572 2021-09-03²FP20-0019-00²
[0033] In Formula (6) or Formula (7), Ar3 is an aryl group that is ²optionally substituted. The aryl group that is optionally substituted in ²Ar3 may have the same definition as in Arl, but Arl and Ar3 are ²preferably groups that are different from each other. A preferable Ar3² is an o-nitro phenyl group, a m-nitro phenyl group, or a p-nitro phenyl²group.²
[0034] The compound (6) is a reagent that acylates hydroxy groups of ²the compound (4). In Formula (6), X is a leaving group. Examples ²of leaving groups include a halogen atom (for example, a fluorine atom,²a chlorine atom, and a bromine atom), and a relatively bulky acyloxy²group (for example, a pivaloyloxy group).²
[0035] In the step 2, for example, as necessary, a solvent, a base and an ²additive are added to the compound (4) in a predetermined container, ²the compound (6) is added thereto, and the mixture is then stirred for a²predetermined time.²
[0036] The reaction may be performed without a solvent or may be ²performed in a solvent. The reaction is preferably performed in an ²organic solvent. The solvent used may be any solvent in which the ²compound (4) and the compound (6) can be dissolved and which does²not inhibit the reaction. Examples of solvents include aromatic²hydrocarbons such as benzene, toluene, and xylene, aliphatic ²hydrocarbons such as hexane and heptane, carboxylate esters such as ²ethyl acetate and isopropyl acetate, halogenated hydrocarbons such as²dichloromethane, 1,2-dichloroethane, chlorobenzene, and²dichlorobenzene, and ethers such as diethyl ether, diisopropyl ether,²tetrahydrofuran, methyl tert-butyl ether, cyclopentyl methyl ether, and²16²Date Recue / Date Received 2021-09-03²<DP=17>²CA 03132572 2021-09-03²FP20-0019-00²2-methyl-tetrahydrofuran. These solvents may be used alone or may ²be used by being selectively mixed. The amount of the solvent used is ²preferably an amount at which the molar concentration of the compound ²(4) is 0.2 to 1.2 mol / L.²
[0037] In order to accelerate the reaction, a base may be added to the²reaction solution. Examples of bases include trialkylamines such as²triethylamine and N,N-diethyl-N-isopropylamine, and²nitrogen-containing aromatic compounds such as pyridine and ²2,6-dimethylpyridine. The amount of the base used varies depending²on the amount of the compound (4), but is preferably 1 to 10 equivalents²with respect to number of moles of the compound (4).²
[0038] In addition, in order to further accelerate the reaction, an ²additive such as 4-dimethylaminopyridine, imidazole, and ²N-methylimidazole may be added thereto. The amount of the additive² used varies depending on the amount of the compound (4) and the type²of the base and the amount of the base used, but is preferably 0.001 to ²0.05 equivalents with respect to the number of moles of the compound ²(4).²
[0039] The reaction can be generally performed at a temperature²applied for the acylation reaction. The reaction temperature may be,²for example, -20 to 60 C, and is preferably 0 to 30 C.²
[0040] The product can be purified by generally used purification ²methods such as extraction, crystallization, distillation, and various²types of chromatography alone or an appropriate combination thereof.²
[0041] (Step 3)²The method according to the present embodiment may further²17²Date Recue / Date Received 2021-09-03²<DP=18>²CA 03132572 2021-09-03²FP20-0019-00²comprise a step of converting the compound (7) into a compound (8) by ²treating it with a base in a solvent. In Formula (8), IV has the same ²definition as in Formula (7).²HQ².õR2² _____________________________________________________ " Step 4 HO OH²0 (la) ²0²Q²R1 _________________________________________________________________ R1²0²Step 3 Step 5 z²oYo'OH HO OH²Ar3 OH (1 b)²Ar', (8) HO²(7) õ R2² _____________________________________________________ >² Step 6 R1² Ho' OH²(1c)²
[0042] In the step 3, for example, a solvent is added to the compound²(7), which are mixed in a predetermined container, a base is added ²thereto, and the mixture is then stirred for a predetermined time.²
[0043] The base in the step 3 may be an organic base or an inorganic ²base. Examples of organic bases include trialkylamines such as²triethylamine and N,N-diethyl-N-isopropylamine, nitrogen-containing²aromatic compounds such as pyridine and 2,6-dimethylpyridine, and ²metal alkoxides such as sodium methoxide, potassium methoxide, ²sodium ethoxide, potassium ethoxide, sodium tert-butoxide, and²potassium tert-butoxide. ²Examples of inorganic bases include²potassium carbonate, sodium carbonate, cesium carbonate, potassium²bicarbonate, sodium bicarbonate, potassium hydroxide, sodium ²hydroxide, tripotassium phosphate, trisodium phosphate, dipotassium ²hydrogen phosphate, disodium hydrogen phosphate, potassium²18²Date Recue / Date Received 2021-09-03²<DP=19>²CA 03132572 2021-09-03²FP20-0019-00²dihydrogen phosphate, and sodium dihydrogen phosphate. The ²amount of the base used varies depending on the amount of the ²compound (7), but is preferably 1 to 10 equivalents with respect to the ²number of moles of the compound (7).²
[0044] Examples of the solvent in the step 3 include aromatic²hydrocarbons such as benzene, toluene, and xylene, aliphatic ²hydrocarbons such as hexane and heptane, halogenated hydrocarbons ²such as dichloromethane, 1,2-dichloroethane, chlorobenzene, and ²dichlorobenzene, ethers such as diethyl ether, diisopropyl ether,²tetrahydrofuran, methyl tert-butyl ether, cyclopentyl methyl ether, and²2-methyl-tetrahydrofuran, alcohols such as methanol, ethanol, isopropyl ²alcohol, n-butyl alcohol, 2-butyl alcohol, tert-butyl alcohol, ethylene ²glycol, propylene glycol, 1,2-propanediol, and glycerin, acetonitrile, ²N,N-dimethylformamide (DMF), and N,N-dimethylacetamide. These² solvents may be used alone or may be used by being selectively mixed.²It preferably comprises water or an alcohol.²
[0045] The amount of the solvent used is preferably an amount at which ²the molar concentration of the compound (7) is 0.05 to 1.0 mol / L and ²more preferably an amount at which the molar concentration of the² compound (7) is 0.1 to 0.5 mol / L.²
[0046] The reaction product can be purified by generally used ²purification methods such as extraction, crystallization, distillation, and ²various types of chromatography alone or an appropriate combination ²thereof.²
[0047] The method according to the present embodiment may further²comprise a step for converting the compound (8) into the compound²19²Date Recue / Date Received 2021-09-03²<DP=20>²CA 03132572 2021-09-03²FP20-0019-00²(la) or (lb). For such a step, the descriptions in Patent Literature 1 to²4 and Non-Patent Literature 1 can be referred to.²
[0048] (Step 4)²The step 4 is a step for obtaining the compound (la), and may² be composed of a plurality of steps. The compound (la) may be, for²example, prostaglandin F2d derivatives such as dinoprost, and²bimatoprost.²
[0049] (Step 5)²The step 5 is a step for obtaining a compound (lb), and may be² composed of a plurality of steps. The compound (lb) may be, for²example, prostaglandin El derivatives such as alprostadil and limaprost,²or prostaglandin E2 derivatives such as dinoprostone.²
[0050] (Step 6)²The step 6 is a step for obtaining a compound (1c) and may be² composed of a plurality of steps. The compound (1c) may be, for²example, prostaglandin F2d derivatives such as latanoprost.²
[0051] Another embodiment of the present invention is a compound ²(7').²o²)1N²0 6²(7')²
[0052] In Formula (7'), R is a C1-8 alkyl group that is unsubstituted or²substituted with a phenyl group. The definition of R is the same as the² Date Recue / Date Received 2021-09-03²<DP=21>²CA 03132572 2021-09-03²FP20-0019-00²definition of R1 in Formula (1a).²
[0053] In Formula (7'), A is a nitro group bonded to any position of an²ortho-position, a meta-position, and a para-position of a benzene ring. ²
[0054] The compound (7') may be a single diastereomer or may be a² mixture of a plurality of diastereomers. In order to produce the²compound (la), (lb), or (lc), the compound (7') preferably has high ²optical purity.²
[0055] The optical purity of the compound (7') can be improved by²performing recrystallization. Examples of solvents used for²crystallization include aromatic hydrocarbons such as benzene, toluene,²and xylene, aliphatic hydrocarbons such as hexane and heptane, ²carboxylate esters such as ethyl acetate and isopropyl acetate, ²halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane, ²chlorobenzene, and dichlorobenzene, ethers such as diethyl ether,²diisopropyl ether, tetrahydrofuran, methyl tert-butyl ether, cyclopentyl²methyl ether, and 2-methyl-tetrahydrofuran, and alcohols such as ²methanol, ethanol, isopropyl alcohol, and 1-butanol. These solvents ²may be used alone or may be used by being selectively mixed. It ²preferably comprises carboxylate ester or an alcohol. A compound²(7') having low optical purity is dissolved in a solvent while heating as²necessary and gradually cooling, and thus a compound (7') having ²higher optical purity can be obtained.²
[0056] The compound (7') has excellent crystallinity, and is useful as a ²production intermediate for producing the compound (la), (lb), or (1c)²having high optical purity.²Examples²21²Date Recue / Date Received 2021-09-03²<DP=22>²CA 03132572 2021-09-03²FP20-0019-00²
[0057] An embodiment of the present invention will be described in ²more detail with reference to examples.²
[0058] The abbreviations used in the following description should be ²generally understood according to common general technical² knowledge in the field. Specifically, the meanings of the abbreviations²are as follows.²Bz: benzoyl²CAN: ammonium hexanitratocerate(IV)²CSA: 10-camphorsulfonic acid² DIBAL-H: diisobutylaluminum hydride²DMAP: 4-dimethylamino pyridine²DMF: N,N-dimethylformamide²Et: ethyl²IPA: isopropyl alcohol² n-: normal²NMR: nuclear magnetic resonance spectrum²p-: para²ph: phenyl²PMB: paramethoxybenzyl² Me-THF: 2-methyl-tetrahydrofuran²TEA: triethylamine²tert: tertiary²THF: tetrahydrofuran²THP: tetrahydropyran-2-y1²
[0059] The 1H-NMR spectrum is shown by a chemical shift value (6)²corrected with tetramethylsilane as an internal standard (0 ppm), and the²22²Date Recue / Date Received 2021-09-03²<DP=23>²CA 03132572 2021-09-03²FP20-0019-00²split pattern is abbreviated as follows. s: singlet, d: doublet, t: triplet, ²q: quartet, dd: double doublet, ddd: double double doublet, dt: double ²triplet, m: multiplet, br: broad.²
[0060] Example 1: Method for producing dinoprostone²)1N²Q 5)C²Step 1² Step 2² / ²0 -6H²OP Bz OBz² (3A) (4A) 0²0²gic²Q²- _______________________ :² / ²5H Step 3 Bzo:² 0H NO2²(8A) 0²(7A)²
[0061] (Step 1)²According to the methods described in Example 1 of Patent ²Literature 5 and Example 8 of Patent Literature 6, a compound (3A) ²was prepared from commercially available (-)-Corey Lactone-Benzoate² (trade name) and dimethy1-2-oxo-heptylphosphonate. The compound²(3A) (20.0 g, 54 mmol) and tripotassium phosphate (1.1 g) were ²suspended in a mixed solution containing THF (100 mL) and ethanol ²(20 mL). A gas phase in a container under an ice bath was replaced ²with nitrogen gas. (R)-RUCY-xylBINAP (commercially available²from Tokyo Chemical Industry Co., Ltd., 0.64 g, 0.52 mmol) was added²to the suspension, a gas phase was then replaced with hydrogen gas, and ²the mixture was stirred for 24 hours. After a gas phase was replaced ²with nitrogen gas, the solvent was distilled off under a reduced pressure, ²and thereby a compound (4A) (a diastereomer excess rate of 87%) was²obtained. The obtained compound (4A) was used in the step 2 without²23²Date Recue / Date Received 2021-09-03²<DP=24>²CA 03132572 2021-09-03²FP20-0019-00²further purification.²
[0062] (Step 2)²Ethyl acetate (50 mL) was added to the compound (4A) to²dissolve it, and TEA (10.9 g) and DMAP (33 mg) were added thereto.² An ethyl acetate solution (40 mL) containing p-nitrobenzoyl chloride²(14.0 g) was added dropwise to the obtained solution, and the mixture ²was stirred for 1 hour. Ethyl acetate was added to the reaction ²solution, washing with water was performed, and an organic layer was ²collected. After the solvent was distilled off under a reduced pressure,²ethanol (100 mL) was added to the obtained residue, and dissolved²while heating, and the mixture was gradually cooled to 0 C to obtain ²crystals. The obtained crystals were washed with ethanol and dried ²under a reduced pressure, and thereby a compound (7A) (21.1 g, 40 ²mmol, 74% yield, a diastereomer excess rate of 99%) was obtained.²mp: 105 C;²iHNIMR (400 MHz, CDC13): 6 8.26-8.21(m, 2H), 8.14-8.09(m, 2H), ²7.91(dd, 2H), 7.53(dd, 1H), 7.38(dd, 2H), 5.76-5.65(m, 2H), 5.46(ddd, ²1H), 5.25(ddd, 1H), 5.06(ddd, 1H), 2.90-2.74(m, 3H), 2.61(ddd, 1H), ²2.51(d, 1H), 2.22(ddd, 1H), 1.74(m, 2H), 1.36-1.26(m, 6H), 0.86(t, 3H);²13CNMR (100 MHz, CDC13): 6 176.1, 165.8, 163.8, 150.4, 135.7, 133.3,²132.0, 131.3, 130.6, 129.5, 129.4, 128.4, 123.5, 83.0, 78.5, 75.8, 53.9,²42.4, 37.5, 34.7, 34.2, 31.4, 24.8, 22.4, 13.9²
[0063] (Step 3)²A methanol solution (100 mL) containing the compound (7A)² (20.0 g, 38 mmol) was ice-cooled, potassium carbonate (10.6 g) was²added thereto, and the mixture was reacted for 4 hours. Phosphoric²24²Date Recue / Date Received 2021-09-03²<DP=25>²CA 03132572 2021-09-03²FP20-0019-00²acid diluted with water was added, and washing with a toluene / hexane ²mixed solution (volume ratio of 1 / 1) was performed. The solvent was ²distilled off under a reduced pressure, the obtained residue was ²extracted with ethyl acetate, and an organic layer was collected. The² solvent of the organic layer was distilled off under a reduced pressure to²obtain a compound (8A) (9.8 g, 37 mmol, 95% yield).²111NMR (400 MHz, CDC13): 6 5.60(dd, 1H), 5.44(dd, 1H), 4.88(ddd, ²1H), 4.08-4.03(m, 1H), 3.97-3.91(m, 1H), 2.78-2.69(m, 1H), ²2.62-2.49(m, 2H)2.47-2.38(m, 2H), 2.31-2.22(m, 2H), 1.98-1.91(m,²1H), 1.63-1.42(m, 2H), 1.38-1.23(m, 6H), 0.89(t, 3H);²13CNMR (100 MHz, CDC13): 6 176.9, 136.8, 130.2, 82.4, 76.3, 72.8,²56.12, 42.34, 39.61, 37.05, 34.0, 31.6, 25.1, 22.5, 13.9)²
[0064] (Step 5)²0 OH²Step 5-1 Step 5-2²Ho OH THP6 OTHP²(8A) (10A)²0 0²COOH²Step 5-3²OH THP6 OTHP²(9A) (11A)² According to the method described in Example 14 of Patent²Literature 7, the compound (8A) (9.8 g, 37 mmol) was converted into a ²compound (10A). The compound (10A) was converted into a ²compound (11A) according to the method described in Example 1 of ²Patent Literature 8, and also converted into a compound (9A) (7.2 g, 19² mmol, 51% yield (Step 3)) with reference to the method described in² Date Recue / Date Received 2021-09-03²<DP=26>²CA 03132572 2021-09-03²FP20-0019-00²Example 14 of Patent Literature 9.²mp: 66 C²1I-INMR (400 MHz, CDC13): 6 5.68(dd, 1H), 5.58(dd, 1H), 5.47-5.34(m,²2H), 4.20-4.10(m, 1H), 4.05(dd, 1H), 2.75(dd, 1H), 2.47-1.93(m, 9H),² 1.82-1.43(m, 4H), 1.40-1.20(m, 6H), 0.89(t, 3H)²13CNMR (100 MHz, CDC13): 6 214.4, 177.6, 136.7, 130.9, 126.9, 73.2,²72.5, 54.6, 53.6, 46.4, 37.2, 33.2, 31.8, 26.4, 25.3, 24.6, 22.8, 14.2²
[0065] In the step 1, catalytic hydrogen reduction was performed in the ²same manner under the following conditions. The reaction conditions²and the results are shown in Table 1.²[Table 1]²26²Date Recue / Date Received 2021-09-03²<DP=27>²FP20-0019-00²Metal complex Reducing Base ²Solvent Reaction %d.e.²Type Amount agent ² temperature²used ² ( C)²Example 2 (R)-RUCY-xylBINAP 3 mol% hydrogen gas K3PO4 ²THF / water 0 90²(5:1)²Example 3 (R)-RUCY-xylBINAP 3 mol% hydrogen gas K3PO4 ²THF / IPA 0 88²(1:1)²Example 4 (R)-RUCY-xylBINAP 1 mol% hydrogen gas K3PO4 ²THF / ethanol -10 94²(5:1)²Example 5 (R)-RUCY-xylBINAP 3 mol% hydrogen gas K3PO4 ²CPME / IPA 25 85²(1:10) ² p²Example 6 (R)-RUCY-xylBINAP 3 mol% hydrogen gas K3PO4 ²IPA 25 85 2²,²Example 7 (R)-RUCY-xylBINAP 3 mol% hydrogen gas Cs2CO3 ²THF / IPA 25 87²u,²(1:10)²Example 8 (R)-RUCY-xylBINAP 3 mol% hydrogen gas K3PO4 Me-²THF / IPA 25 86 2²,²(2:20)²Comparative RuCl[(R,R)-Tsdpen](p-cymene) 1 mol% formic acid TEA ²THF 60 16 I²w²Example 1²Comparative RuC1[(R,R)-Tsdpen](mesitylene) 1 mol% formic acid TEA ²THF 60 9²Example 2²Comparative Ru[(R,R)-Tsdpen](p-cymene) 1 mol% formic acid TEA ²THF 60 20²Example 3²Comparative RuCl[(R,R)-Msdpen](p-cymene) 1 mol% formic acid TEA ²THF 60 36²Example 4²Comparative R(R,R)-Ts-DENEB 1 mol% formic acid TEA ²THF 25 -13²Example 5²27²Date Recue / Date Received 2021-09-03²<DP=28>²CA 03132572 2021-09-03²FP20-0019-00²
[0066] Example 9: Method for producing limaprost²Q z² ____________________________________________________________ S²Step 1 tep 2²0²OBz OBz 0²(3B) (4B)²Q²Q -²b² / Step 3 n²OBz ¨²OH²(8B)²(7B) NO2²
[0067] (Step 1)²With reference to the method described in Patent Literature 5² and 6, a compound (3B) was prepared from commercially available²(-)-Corey Lactone-Benzoate (trade name) ²and²dimethy1-2-oxo-4-methyloctylphosphonate.²iHNIMR (300 MHz, CDC13): 6 8.02-7.96(m, 2H), 7.62-7.55(m, 1H), ²7.50-7.42(m, 2H), 6.68(dd, 1H), 6.24(d, 1H), 5.33(q, 1H), 5.14-5.08(m,²1H), 2.96-2.85(m, 3H), 2.68-2.28(m, 5H), 2.05-1.93(m, 1H),²1.32-1.15(m, 6H), 0.92-0.84(m, 6H)²With reference to the method described in Example 1, a ²compound (4B) (a diastereomer excess rate of 87%) was obtained from ²the compound (3B) (20.0 g, 50 mmol).²
[0068] (Step 2)²With reference to the method described in Example 1, a²compound (7B) (18.1g, 33 mmol, 66% yield, a diastereomer excess rate²of 97%) was obtained from the compound (4B).²mp: 74 C;²28²Date Recue / Date Received 2021-09-03²<DP=29>²CA 03132572 2021-09-03²FP20-0019-00²11-INMR (400 MHz, CDC13): 6 8.22-8.19(m, 2H), 8.10-8.07(m, 2H), ²7.90-7.88(m, 2H), 7.52-7.49(m, 1H), 7.37-7.33(m, 2H), 5.77-5.71(m, ²1H), 5.67-5.61(m, 1H), 5.53(dd, 1H), 5.23(dd, 1H), 5.04(ddd, 1H), ²2.89-2.71(m, 3H), 2.59(ddd, 1H), 2.49(d, 1H), 2.20(ddd, 1H), 1.64(t,² 2H), 1.49-1.41(m, 1H), 1.26-1.10(m, 6H), 0.91(d, 3H), 0.85(t, 3H);²13CNMR (100 MHz, CDC13): 6 176.2, 165.9, 163.9, 150.5, 135.9, 133.4, ²132.4, 131.5, 130.7, 129.6, 128.5, 123.6, 83.1, 78.6, 74.7, 54.0, 42.5, ²41.5, 37.6, 36.6, 34.8, 29.5, 29.0, 23.0, 19.9, 14.2²
[0069] (Step 3)² With reference to the method described in Example 1, a²compound (8B) (9.2 g, 31 mmol, 95% yield) was obtained from the ²compound (7B) (18.1 g, 33 mmol).²11-INMR (400 MHz, CDC13): 6 5.56(dd, 1H), 5.44(dd, 1H), 4.88(ddd, ²1H), 4.17-4.08(m, 1H), 3.96-3.89(m, 1H), 2.78-2.21(m, 6H), 1.93(ddd,²1H), 1.87(br, 1H), 1.63(Br, 1H), 1.45-1.08(m, 9H), 0.93-0.82(m, 6H)²
[0070] (Step 5)²ojc)²__________________________________________________________________ Step 5-2²Step 5-1²HO OH PMBO. PMBO²(8B) (10B) 2E1²=²PMBO PMBO²(11B)²HQ HQ;² Step 5-3²Step 5-4 ,-²PMBO PMBO PMBO pmB0 - (0,²(14B) (13B) BrPh3P (12B)²
[0071] (Step 5-1)²(3aR,4R,5R,6a5)-5- [(4-methoxybenzyl)oxy] -4- { (3 S ,5S ,E)-3- [(4-metho²29²Date Recue / Date Received 2021-09-03²<DP=30>²CA 03132572 2021-09-03²FP20-0019-00²xybenzyl)oxy]-5-methylnon-l-en-l-ylf hexahydro-2H-cyclopenta[b]fura ²n-2-one (10B)²Dichloromethane (3 mL) was added to the compound (8B) (0.29 ²g, 0.98 mmol) to dissolve it, 4-methoxybenzyl 2, 2,² 2-trichloroacetoimidate (0.69 g) and CSA (0.01 g) were added thereto,²and the mixture was stirred at room temperature. A saturated sodium ²bicarbonate aqueous solution and ethyl acetate were added to the ²reaction solution, the mixture was filtered with diatomite, and the ²solvent was distilled off under a reduced pressure. The residue was²purified through supercritical fluid chromatography (device name:²Viridis CSH Fluoro-Phenyl OBD Prep Column, carbon ²dioxide / methanol / chloroform=90 / 5 / 5 to 80 / 10 / 10), and thereby a ²compound (10B) (0.374 g, 71% yield) was obtained.²1I-INMR (400 MHz, CDC13): 6 7.25-7.16(m, 4H), 6.88-6.83(m, 4H),² 5.48(dd, 1H), 5.41(dd, 1H), 4.98-4.93(m, 1H), 4.57-4.21(m, 4H),²3.81-3.73(m, 8H), 2.79-2.61(m, 3H), 2.53-2.46(m, 1H), 2.34-2.11(m,²2H), 1.55-1.02(m, 7H), 0.91-0.82(m, 6H)²
[0072] (Step 5-2)²(3aR,4R,5R,6a5)-5-[(4-methoxybenzyl)oxy]-4- { (3 S ,5S ,E)-3- [(4-metho²xybenzyl)oxy]-5-methylnon-l-en-l-ylf hexahydro-2H-cyclopenta[b]fura²n-2-ol (11B)²The compound (10B) (0.370 g, 0.69 mmol) was dissolved in ²dichloromethane (7 mL), and DIBAL-H (1 mol / L hexane solution, ²0.758 mL) was gently added dropwise thereto at -78 C. The mixture² was stirred at -78 C for 30 minutes, a saturated Rochelle salt aqueous²solution was then added, the mixture was stirred at room temperature² Date Recue / Date Received 2021-09-03²<DP=31>²CA 03132572 2021-09-03²FP20-0019-00²for 30 minutes, ethyl acetate was added thereto, the mixture was filtered ²with diatomite, and the solvent was distilled off under a reduced²pressure. The ²residue was purified through silica gel column²chromatography (heptane / ethyl acetate=2 / 1 to 1 / 1), and thereby a² compound (11B) (0.348 g, 94% yield) was obtained.²iHNIMR (400 MHz, CDC13): 6 7.25-7.18(m, 4H), 6.87-6.79(m, 4H), ²5.68-5.36(m, 3H), 4.68-4.20(m, 5H), 3.81-3.69(m, 8H), 2.52-2.17(m, ²4H), 2.06-1.77(m, 2H), 1.54-1.36(m, 3H), 1.29-0.99(m, 7H), ²0.91-0.82(m, 6H)²
[0073] (Step 5-3)²(1S ,2R,3R,4R)-2- [(Z)-4-(1,3-dioxolane-2-yl)but-2-en-1 -yl] -4- [(4-metho ²xybenzypoxy] -3- f (3S ,5S ,E)-3-[(4-methoxybenzypoxy]-5-methylnon-1-²en-l-ylf cyclopentanol (13B)²The compound (12B)² (2-(1,3-dioxolane-2-yl)ethyltriphenylphosphonium bromide, 1.40 g,²3.16 mmol) was suspended in THF (6 mL), potassium tert-butoxide ²(0.354 g, 3.16 mmol) was added, and the mixture was stirred at room ²temperature for 30 minutes. A THF (2 mL) solution containing the ²compound (11B) (0.340 g, 0.631 mmol) was added dropwise to a brown²suspension reaction solution under ice-cooling and the mixture was²stirred at 0 C for 30 minutes. A saturated ammonium chloride ²aqueous solution and ethyl acetate were added to the reaction solution, ²the mixture was filtered with diatomite, and the solvent was distilled off ²under a reduced pressure. The residue was purified through silica gel²column chromatography (heptane / ethyl acetate=4 / 1 to 2 / 1, and then²chloroform / methano1=50 / 1 to 30 / 1), and thereby a compound (13B)²31²Date Recue / Date Received 2021-09-03²<DP=32>²CA 03132572 2021-09-03²FP20-0019-00²(0.258 g, 66% yield) was obtained as a white solid.²iHNIMR (400 MHz, CDC13): 6 7.25-7.18(m, 4H), 6.86-6.79(m, 4H), ²5.56-5.40(m, 4H), 4.93-4.89(m, 1H), 4.54-4.22(m, 4H), 4.13-4.07(m, ²1H), 4.01-3.83(m, 4H), 3.81-3.74(m, 8H), 3.01-2.97(m, 1H),² 2.68-2.55(m, 2H), 2.45-2.34(m, 2H), 2.18-1.99(m, 2H), 1.90-1.83(m,²1H), 1.56-1.37(m, 4H), 1.30-1.01(m, 6H), 0.89-0.82(m, 6H)²
[0074] (Step 5-4)²(1S ,2R,3R,4R)-2- [4-(1,3-dioxolane-2-yl)butyl]-4- [(4-methoxybenzyl)ox²y] -3- { (3 S ,5 S ,E)-3- [(4-methoxyb enzypoxy] -5-methylnon-1-en-l-ylf cycl²opentanol (14B)²The compound (13B) (0.250 g, 0.401 mmol) was dissolved in ²ethyl acetate (3 mL), RhC1(PPh3)3 (0.074 g, 0.080 mmol) was added, ²and the mixture was stirred under a hydrogen atmosphere at room ²temperature for 5 hours. The reaction solution was concentrated under² a reduced pressure, and the obtained residue was purified through silica²gel column chromatography (heptane / ethyl acetate=4 / 1 to 2 / 1), and then ²amino silica gel column chromatography (heptane / ethyl acetate=4 / 1 to ²2 / 1), and thereby a compound (14B) (0.208 g, 83% yield) was obtained ²as a white solid.²iHNIVIR (400 MHz, CDC13): 6 7.25-7.18(m, 4H), 6.87-6.81(m, 4H),²5.48(dd, 1H), 5.38(dd, 1H), 4.86-4.81(m, 1H), 4.52-4.21(m, 4H), ²4.18-4.12(m, 1H), 3.98-3.91(m, 2H), 3.86-3.73(m, 10H), 2.54-2.47(m, ²1H), 2.20-1.95(m, 3H), 1.72-1.02(m, 18H), 0.91-0.81(m, 6H)²
[0075] ²32²Date Recue / Date Received 2021-09-03²<DP=33>²CA 03132572 2021-09-03²FP20-0019-00²HO²Ph3P(7'602Me HQ²= ,CO2Me²(16B)² __________________________________________________________________ Step 5-6²Step 5-5²PMBC; PMB6 PMBO pmso HQ²= CO2H² (14B) (17B)² PMB6 pkin85²0 0 (18B)² Step 5 Step 5-7²-8²HO 6H PMB6 PMB6² (9B) (19B)²
[0076] (Step 5-5)²(E)-methyl²7-((1R,2R,3R,5S)-5-hydroxy-3 - [(4-methoxybenzyl)oxy] -2- { (3 S ,5S ,E)-3²-[(4-methoxybenzyl)oxy]-5-methylnon-l-en-l-ylf cyclopentyl)hept-2-en²oate (17B)²The compound (14B) (0.190 g, 0.304 mmol) was dissolved in ²THF (4 mL), 6 mol / L hydrochloric acid (2 mL) was added under ²ice-cooling, and the mixture was stirred at room temperature overnight.² A saturated sodium bicarbonate aqueous solution was added to the²reaction solution and extraction with ethyl acetate was performed. An ²organic layer was washed with a saturated saline solution and dried with ²anhydrous magnesium sulfate, and the solvent was distilled off under a ²reduced pressure. The residue was purified through silica gel column²chromatography (heptane / ethyl acetate=2 / 1 to 1 / 1), and thereby a crude²purified product of a compound (15B) was obtained as a white solid. ²The obtained crude purified product was dissolved in dichloromethane ²(4 mL), methyl(triphenylphosphoraniliden)acetate (16B) (0.508 g, 1.52 ²mmol) was added under ice-cooling, and the mixture was stirred at² room temperature for 2 hours. The reaction solution was purified²through silica gel column chromatography (heptane / ethyl acetate=2 / 1 to²33²Date Recue / Date Received 2021-09-03²<DP=34>²CA 03132572 2021-09-03²FP20-0019-00²1 / 1), and thereby a compound (17B) (0.131 g, 68% yield) was obtained ²as a white solid.²
[0077] (Step 5-6)²(E)-7-((1R,2R,3R,5S)-5-hydroxy-3-[(4-methoxybenzypoxy]-2- { (3 S ,5 S ,² E)-3-[(4-methoxybenzyl)oxy]-5-methylnon-1-en-l-ylf cyclopentyl)hept-²2-enoic acid (18B)²The compound (17B) (0.0900 g, 0.141 mmol) was suspended in ²ethanol (2 mL), a 1 mol / L potassium hydroxide aqueous solution (0.565 ²mL, 0.565 mmol) was added under ice-cooling, and the mixture was² stirred at 40 C or 3 hours. lmol / L hydrochloric acid (0.60 mL) and²ethyl acetate were added to the reaction solution under ice-cooling, and ²the mixture was filtered with diatomite. The solvent was distilled off ²under a reduced pressure. The residue was purified through silica gel ²column chromatography (heptane / ethyl acetate=4 / 1 to 2 / 1, and then²chloroform / methano1=20 / 1 to 10 / 1), and thereby a compound (18B)²(0.0826 g, 94% yield) was obtained as a white solid.²iHNMR (400 MHz, CDC13): 6 7.24-7.17(m, 4H), 7.04(dt, 1H), ²6.87-6.81(m, 4H), 5.81(dt, 1H), 5.49(dd, 1H), 5.39(dd, 1H), ²4.53-4.23(m, 4H), 4.17-4.12(m, 1H), 3.86-3.72(m, 8H), 2.55-2.46(m,²1H), 2.26-2.19(m, 2H), 2.02-1.93(m, 2H), 1.68-1.03(m, 17H),²0.91-0.81(m, 6H)²
[0078] (Step 5-7)²(E)-7-((1R,2R,3R)-3- [(4-methoxybenzyl)oxy] -2- { (3 S ,5S ,E)-3- [(4-meth²oxybenzyl)oxy]-5-methylnon-l-en-l-ylf -5-oxocyclopentyl)hept-2-enoic²acid (19B)²The compound (18B) (80.0 mg, 0.128 mmol) was dissolved in²34²Date Recue / Date Received 2021-09-03²<DP=35>²CA 03132572 2021-09-03²FP20-0019-00²dichloromethane (1 mL), Dess-Martin Periodinane (109 mg, 0.257 ²mmol) was added under ice-cooling, and the mixture was stirred at ²room temperature for 2 hours. Water and ethyl acetate were added to ²the reaction solution, the mixture was filtered with diatomite, and the² solvent was distilled off under a reduced pressure. The residue was²purified through silica gel column chromatography ²(chloroform / methano1=20 / 1 to 10 / 1, and then heptane / ethyl ²acetate=1 / 1), and thereby a compound (19B) (80.0 mg, quantitative ²yield) was obtained as colorless and transparent oil.²iHNMR (400 MHz, CDC13): 6 7.24-7.18(m, 4H), 7.02(dt, 1H),²6.87-6.80(m, 4H), 5.80(dt, 1H), 5.61(dd, 1H), 5.52(dd, 1H), ²4.56-4.25(m, 4H), 3.92-3.75(m, 8H), 2.77-2.59(m, 2H), 2.28-2.16(m, ²3H), 2.02-1.94(m, 1H), 1.69-1.03(m, 18H), 0.90-0.83(m, 6H)²
[0079] (Step 5-8)²(E)-7- {(1R,2R,3R)-3-hydroxy-2-[(3S ,55 ,E)-3-hydroxy-5-methylnon-l-e²n-l-y1]-5-oxocyclopentylfhept-2-enoic acid (9B)²The compound (19B) (10.0 mg, 16.0 mop was dissolved in a ²mixed solvent containing acetonitrile (0.5 mL) and water (0.05 mL), ²CAN (35.3 mg, 64.0 mop was added under ice-cooling, and the² mixture was stirred at room temperature for 30 minutes. Under²ice-cooling, ethyl acetate was added, and extraction in a saturated²sodium bicarbonate aqueous solution was performed. lmol / L ²hydrochloric acid was added to an aqueous layer until the liquid reached ²a pH of 5, and extraction with ethyl acetate was performed. An²organic layer was washed with a saturated saline solution and dried with²anhydrous magnesium sulfate, and the solvent was distilled off under a² Date Recue / Date Received 2021-09-03²<DP=36>²CA 03132572 2021-09-03²FP20-0019-00²reduced pressure. The residue was purified through silica gel column ²chromatography (chloroform / methano1=20 / 1 to 10 / 1), and thereby a ²compound (9B) (4.4 mg, 74% yield) was obtained.²11-1NMR (400 MHz, CDC13): 6 7.00(dt, 1H), 5.81(d, 1H), 5.66(dd, 1H),² 5.56(dd, 1H), 4.25-4.17(m, 1H), 4.11-4.01(m, 1H), 3.40(br, 1H),²2.75(dd, 1H), 2.41-2.32(m, 1H), 2.27-2.14(m, 3H), 2.08-1.97(m, 1H), ²1.67-1.11(m, 16H), 0.95-0.84(m, 6H)²
[0080] Example 10: Method for producing latanoprost²Ph ____________________________ ²Ph²Step 1 / Step 2² 0 OH²OBz OBz² (3C) (4C) 0²0 0-1c²Ph Ph²'OH Step 3 Bzo: 0²OH NO2² (8C) (7C) 0²
[0081] (Step 1)²With reference to the method described in Patent Literature 5, a ²compound (3C) was prepared from commercially available (-)-Corey²Lactone-Benzoate (trade name) and²dimethy1-2-oxo-4-phenylbutylphosphonate. In the same manner as in² Example 1, a compound (4C) (a diastereomer excess rate of 80%) was²obtained from the compound (3C) (20.0 g, 49 mmol).²
[0082] (Step 2)²In the same manner as in Example 1, a compound (7C) (20.0 g,²36 mmol, 74% yield (Step 2), a diastereomer excess rate of 99%) was²36²Date Recue / Date Received 2021-09-03²<DP=37>²CA 03132572 2021-09-03²FP20-0019-00²obtained from the compound (4C).²1I-INMR (400 MHz, CDC13): 6 8.22-8.19(m, 2H), 8.07-8.03(m, 2H), ²7.91-7.89(m, 2H), 7.52-7.48(m, 1H), 7.37-7.33(m, 2H), 7.26-7.17(m, ²2H), 7.16-7.10(m, 3H), 5.74-5.67(m, 2H), 5.51-5.46(m, 1H),² 5.25-5.21(m, 1H), 5.05-5.01(m, 1H)2.88-2.46(m, 7H), 2.23-1.99(m,²3H);²13CNMR (100 MHz, CDC13): 6 176.2, 165.9, 163.8, 150.6, 140.8, 135.6, ²133.4, 132.5, 130.9, 130.7, 129.6, 129.4, 128.7, 128.5, 128.4, 126.3, ²123.6, 83.1, 78.6, 77.5, 77.1, 76.8, 75.3, 54.0, 42.5, 37.5, 35.8, 34.8,²31.6²
[0083] (Step 3)²A compound (8C) was obtained from the compound (7C)²according to the method described in Patent Literature 1.²
[0084] (Step 6)²crkjõ HO II²ph HO OH Step 6-1 HO OH Step 6-2²HO OH²: ² (8C) (1DC) (9G)²According to the method described in Example 7 of Patent ²Literature 5, a compound (10C) was obtained from the compound (8C) ²(5.0 g, 9.0 mmol). In addition, according to the method described in ²Patent Literature 4, a compound (9C) (1.1 g, 2.5 mmol, 28% yield (Step² 3)) was obtained from the compound (10C).²1I-INMR (400 MHz, CDC13): 6 7.29-7.23(m, 2H), 7.21-7.17(m, 3H), ²5.48-5.43(m, 1H), 5.41-5.36(m, 1H), 4.99(m, 1H), 4.16(m, 1H), 3.94(m, ²1H), 3.66(m, 1H), 2.82-2.77(m, 3H), 2.70-2.09(m, 8H)1.90-1.31(m,²37²Date Recue / Date Received 2021-09-03²<DP=38>²CA 03132572 2021-09-03²FP20-0019-00²12H), 1.22(d, 6H);²13CNMR (100 MHz, CDC13): 6 173.5, 142.1, 129.6, 129.3, 128.4, 125.8,²78.8, 74.7, 71.3, 67.7, 52.9, 51.9, 42.5, 39.0, 35.8, 34.0, 32.1, 29.6, 26.9,²26.6, 24.9, 21.8.² 38²Date Recue / Date Received 2021-09-03²
Claims
<DP=1>²CA 03132572 2021-09-03²FP20-0019-00²CLAIMS²1 . A method for producing a compound represented by Formula ²(la), (lb), or (lc), comprising:²HQ R2 0 R2 HQ R2²R1² H OH² OH OH OH²(I a) (1 b) (1c)²in the formula, R1 is a C1_8 alkyl group that is optionally²substituted with a phenyl group, R2 is a group represented by Formula ²(2a), (2b) or (2c):²0 0 \ 0²R3 R3 R3²(2a) (2b) (2c)²in the formula, R3 is a hydroxy group, a C1-3 alkoxy group, a² mono(C1-3 alkyl)amino group or a di(Ci_3 alkyl)amino group;²the method comprising a step of reducing a compound ²represented by Formula (3) in the presence of a metal complex ²represented by Formula (5), an inorganic base, and a solvent under a²hydrogen atmosphere to obtain a compound represented by Formula (4):²0 0²11.²²Q Ar2 Ar2² / FNI2²rP\RTut / ²oyb²p L N²\² Ar2 Ar2 H2²Ar1 Ar1² (3) (4) (5)²in the formula, Ar1 is an aryl group that is optionally substituted, ²each Ai' is independently a phenyl group, a 3,5-dimethylphenyl²39²Date Recue / Date Received 2021-09-03²<DP=2>²CA 03132572 2021-09-03²FP20-0019-00²group, or a 3,5-di(tert-buty1)-4-methoxyphenyl group,²W is a biphenyl group that is optionally substituted or a ²binaphthyl group that is optionally substituted,²Z is an ethylene group that is substituted with two or more² groups selected from among a phenyl group, a C1_3 alkoxyphenyl group²and a C1-8 alkyl group, and L is a chlorine atom, or if Z has a phenyl ²group or a C1-3 alkoxyphenyl group, L is one of carbon atoms ²constituting the phenyl group or the C1-3 alkoxyphenyl group.²2. The method according to claim 1, wherein the solvent comprises²1 0 at least one solvent selected from among ethers, alcohols, and²acetonitrile.²3. The method according to claim 1 or 2, wherein AO is a phenyl ²group, and Ai' is a 3,5-dimethylphenyl group.²4. The method according to any one of claims 1 to 3, wherein IV is²a n-pentyl group, a 2-methylhexyl group, or a 2-phenylethyl group.²5. The method according to any one of claims 1 to 4, further ²comprising²a step of reacting a compound represented by Formula (4) with a ²compound represented by Formula (6) to obtain a compound²represented by Formula (7):²o²Q)c ,-²0....< :R1²0 X Oyo². / ²Ar3²Ar3 Ar1²(6) (7)²in the formula, IV is a C1_8 alkyl group that is optionally² Date Recue / Date Received 2021-09-03²<DP=3>²CA 03132572 2021-09-03²FP20-0019-00²substituted with a phenyl group, Ar1 and AO are each independently an ²aryl group, and X is a leaving group.²6. A compound represented by Formula (7'):²0²A.²Q 2.-²0.....v.,,:<- R²b²o b ² / k A²-õ,²(7')² in the formula, R is a C1_8 alkyl group that is optionally ²substituted with a phenyl group, and A is a nitro group.²41²Date Recue / Date Received 2021-09-03²
